All In Biotech

Drug Trial Radar · NCT00569127

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

427

Actual

Start

Dec 1, 2007

Primary completion

Jan 1, 2015

Study completion Jan 31, 2027

Sponsor

Sponsor type
NIH
First posted
Dec 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving octreotide acetate together with recombinant interferon alfa-2b is more effective than giving octreotide acetate together with bevacizumab in treating patients with neuroendocrine tumor.

Conditions

  • Colorectal Neuroendocrine Tumor G1
  • Gastric Neuroendocrine Tumor G1
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumor
  • Neuroendocrine Tumor G2

Interventions

  • BevacizumabBiological

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Octreotide AcetateDrug

    Given IM

  • Recombinant Interferon Alfa-2bBiological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Central Review-based Progression-Free SurvivalTime frame: Up to 3 years

Locations

493 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Hospital

    Mobile, Alabama

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Arroyo Grande Community

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Marin General Hospital

    Greenbrae, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Kaiser Permanente - Panorama City

    Panorama City, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • Kaiser Permanente-Rio San Diego

    San Diego, California

  • Kaiser Permanente-San Diego Zion

    San Diego, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Kaiser Permanente-San Marcos

    San Marcos, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • Kaiser Permanente-Woodland Hills

    Woodland Hills, California

  • San Luis Valley Regional Medical Center

    Alamosa, Colorado

  • The Medical Center of Aurora

    Aurora, Colorado

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Boulder Community Foothills Hospital

    Boulder, Colorado

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

Showing 40 of 493 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.